Related Experiment Video
Updated: Oct 24, 2025
Murine Fecal Isolation and Microbiota Transplantation
Published on: May 26, 2023
Oral Angiotensin-(1-7) Peptide Modulates Intestinal Microbiota Improving Metabolic Profile in Obese Mice
Amanda Machado1, Janaína Ribeiro Oliveira1, Deborah de F Lelis1
1Laboratory of Health Science, Postgraduate Program in Health Sciences, Universidade Estadual de Montes Claros (UNIMONTES), Montes Claros, Minas Gerais, Brazil.
Background:
Obesity is a serious health problem that dysregulate Renin-Angiotensin System (RAS) and intestinal microbiota.
Objective:
The present study aimed to evaluate the Angiotensin-(1-7) [ANG-(1-7)] oral formulation effects on obese mice intestinal microbiota.
Methods:
Mice were divided into four groups: obese and non-obese treated with ANG-(1-7) and obese and non-obese without ANG-(1-7) during four weeks.
Results:
We observed a significant decrease in the fasting plasma glucose, total cholesterol, triglycerides, and Low-density lipoprotein levels and increased High-density lipoprotein in animals treated with ANG-(1-7). The histological analysis showed intestinal villi height reduction in mice treated with ANG-(1-7). Additionally, increased Bacteroidetes and decreased Firmicutes (increased Bacteroidetes/ Firmicutes ratio) and Enterobacter cloacae populations were observed in the High-Fat Diet + ANG-(1-7) group. Receptor toll-like 4 (TLR4) intestinal mRNA expression was reduced in the HFD+ANG-(1-7) group. Finally, the intestinal expression of the neutral amino acid transporter (B0AT1) was increased in animals treated with ANG-(1-7), indicating a possible mechanism associated with tryptophan uptake.
Conclusion:
The results of the present study suggest for the first time an interaction between oral ANG-(1-7) and intestinal microbiota modulation.
Insights
Oral Angiotensin-(1-7) [ANG-(1-7)] modulated intestinal microbiota in obese mice, improving metabolic markers and altering gut bacteria composition. This suggests a novel interaction between ANG-(1-7) and the gut microbiome.
Area of Science:
- Microbiology
- Endocrinology
- Gastroenterology
Background:
- Obesity is a significant health issue linked to Renin-Angiotensin System (RAS) dysregulation and altered intestinal microbiota.
- The interplay between obesity, RAS, and gut bacteria is complex and warrants further investigation.
Purpose of the Study:
- To investigate the effects of an oral Angiotensin-(1-7) [ANG-(1-7)] formulation on the intestinal microbiota of obese mice.
- To explore potential mechanisms linking ANG-(1-7) treatment to metabolic improvements and gut health.
Main Methods:
- Mice were divided into four groups: obese and non-obese, with and without ANG-(1-7) treatment for four weeks.
- Evaluated metabolic parameters (glucose, lipids), intestinal histology, gut microbiota composition (Bacteroidetes/Firmicutes ratio), and gene expression (TLR4, B0AT1).
Main Results:
- ANG-(1-7) treatment significantly improved metabolic profiles, reducing glucose, cholesterol, and triglycerides while increasing HDL.
- Histological analysis revealed reduced intestinal villi height. Microbiota analysis showed an increased Bacteroidetes/Firmicutes ratio and reduced Enterobacter cloacae.
- Intestinal TLR4 expression decreased, while the neutral amino acid transporter B0AT1 increased, suggesting enhanced tryptophan uptake.
Conclusions:
- Oral ANG-(1-7) administration demonstrates a significant interaction with and modulation of the intestinal microbiota in obese mice.
- These findings highlight a potential therapeutic role for ANG-(1-7) in managing obesity-related metabolic dysfunction through gut microbiome manipulation.
More Related Videos
07:15An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
Published on: July 31, 2019
08:14A Method to Define the Effects of Environmental Enrichment on Colon Microbiome Biodiversity in a Mouse Colon Tumor Model
Published on: February 28, 2018
